Clinical Study

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks

Table 6

Comparison of pretreatment factors between patients with and without 2-week virological response.

FactorsWeek 2 response (≥4.56-log reduction) ( = 21)Non-week-2-response (<4.56-log reduction) ( = 12)

Age (years)58620.618
Sex (male/female)13/85/70.300
Height (cm)162.8158.30.291
Weight (kg)65.857.50.175
BMI24.722.00.593
Baseline HCV-RNA (LogIU/mL; TaqMan)6.86.20.013
Baseline HCV-RNA (LogIU/mL; AccuGene)6.25.50.005
Baseline HCV core Ag (fmol/L)6134.91485.30.003
No response to prior PEG-IFN and ribavirin130.125
Fatty liver600.065
Cirrhosis780.083
Diabetes mellitus 321.000
IL28B (major/minor)15/66/60.274
Core 70 (wild/mutant)12/86/60.718
Core 91 (wild/mutant)15/58/40.696
WBC (/mm3)516044350.175
Hb (g/dL)14.814.10.022
Platelets (/mm3)16.714.80.345
ALT (IU/L)51.043.50.927
γ-GT (IU/L)34.038.00.868
Type VI collagen 7S (ng/mL)4.84.80.811
Hyaluronic acid (ng/mL)94.0105.20.671
AFP (ng/mL)4.56.70.811
Reduced dose regimen15120.065

Values are expressed as the median. BMI, body mass index; HCV, hepatitis C virus; Ag, antigen; IL, interleukin; WBC, white blood cells; Hb, hemoglobin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transferase; AFP, alpha-fetoprotein.